Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-Acquired Pneumonia in Hospitalized US Adults

(2021) Raul Isturiz et al.   CLINICAL INFECTIOUS DISEASES

Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH)

(2021) Joon-Young Song et al.   VACCINE

A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE)

(2021) Heather L. Platt et al.   VACCINE

A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age

(2021) Nicola P. Klein et al.   VACCINE

Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older

(2021) Ulrike K. Buchwald et al.   Human Vaccines & Immunotherapeutics

Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV

(2021) Lerato Mohapi et al.   AIDS

13. The Efficacy and Effectiveness of Pneumococcal Vaccines against Pneumococcal Pneumonia among Adults: A Systematic Review and Meta-Analysis

(2021) Lana Childs et al.   Open Forum Infectious Diseases

21. Systematic Review and Meta-Analysis of Pneumococcal Vaccine Effectiveness against Invasive Pneumococcal Disease among Adults

(2021) Jennifer Loo Farrar et al.   Open Forum Infectious Diseases

Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age

(2020) Donald Hurley et al.   CLINICAL INFECTIOUS DISEASES

Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study

(2020) Hannah Lawrence et al.   PLOS MEDICINE

Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study

(2019) Jong Hun Kim et al.   VACCINE

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices

(2019) Almea Matanock et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Rates of hospitalization for community-acquired pneumonia among US adults: A systematic review

(2019) John M. McLaughlin et al.   VACCINE

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age

(2018) Susan J. Ermlich et al.   VACCINE

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

(2018) James T. Peterson et al.   Human Vaccines & Immunotherapeutics

Initial Serological Response after Prime-boost Pneumococcal Vaccination in Rheumatoid Arthritis Patients: Results of a Randomized Controlled Trial

(2017) Mai T.T. Nguyen et al.   JOURNAL OF RHEUMATOLOGY

Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study

(2017) Motoi Suzuki et al.   LANCET INFECTIOUS DISEASES

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50 years of age: Results from a phase III, randomized, non-inferiority trial

(2017) Opokua Ofori-Anyinam et al.   VACCINE

Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

(2015) Miwako Kobayashi et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine–naïve adults 60–64 years of age

(2014) Richard N. Greenberg et al.   VACCINE

Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older

(2013) Lisa A. Jackson et al.   VACCINE

The epidemiologic evidence underlying recommendations for use of pneumococcal polysaccharide vaccine among American Indian and Alaska Native populations

(2011) Maria A. Said et al.   VACCINE

Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Alaska Native Adults 55–70 Years of Age

(2009) Karen M. Miernyk et al.   CLINICAL INFECTIOUS DISEASES